Evaluate the immunogenicity and safety of GSK [GlaxoSmithKline] Biological's HPV [human papillomavirus]-16/18 L1/AS04 vaccine [human papillomavirus vaccine MEDI-517] administered intramuscularly according to a 0,1,6 mth [month] schedule in healthy female subjects aged 10-14 yrs [years].
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Hepatitis A vaccine inactivated
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 18 Jan 2007 Status change from in progress to completed.
- 04 Dec 2006 New trial record.